2nd Workshop on Prevention Trials in Infants Born to HIV-Positive Mothers
Antiretroviral (ARV) drugs can efficiently reduce HIV-1 mother-to-child transmission (MTCT), but there are still 150,000 infant infections every year. Late HIV-1 diagnosis of pregnant/lactating women, presentation at delivery, delivery outside of public health systems, and breast milk transmission are major challenges for implementing effective prevention strategies. There is a need to develop novel approaches to prevention of infant infections, especially those that may overcome problems of access to ARV, acceptability, adherence, resistance, and stigma.
The Global HIV Vaccine Enterprise is organizing a one and a half-day workshop that will bring together key experts in the field to discuss the conduct of efficacy trials of potential new immune-based approaches to interrupt MTCT of HIV, such as vaccines or passive immunization with monoclonal antibodies. The workshop is a follow-up on the Enterprise-organized meeting held in 2013 in Entebbe, Uganda. The meeting will assess the state of the field, identify gaps responsible for the remaining infant infections, and discuss the various aspects of conducting efficacy trials in the affected populations, using as a case study the proposed trial of a long-lasting broadly neutralizing antibody VRC01-LS in the context of standard of care prevention practices. The agenda for the meeting is still being developed and will be posted here in the near future. The meeting is by invitation only, but the outcomes of these discussions will be shared with the wider research community.
Date: February 6-7, 2017
Radisson Blu Hotel & Residence
A meeting report and a webinar to present the meeting outcomes to a larger audience.
Coleen Cunningham, Duke University
Barney Graham, Vaccine Research Center, NIH
Ilesh Jani, Instituto Nacional de Saúde, Mozambique
Philippa Musoke, Makerere University
Sallie Permar, Duke University
Gabriella Scarlatti, Global HIV Vaccine Enterprise
Yegor Voronin, Global HIV Vaccine Enterprise
If you have any questions about the meeting, please contact Yegor Voronin at firstname.lastname@example.org